Effect of APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study - PubMed
8 hours ago
- #APOC3 Inhibition
- #Triglyceride Lowering
- #Coronary Atherosclerosis
- Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III, reduces triglycerides by ~60% and remnant cholesterol by ~70% in moderate hypertriglyceridemia.
- The study investigated olezarsen's effect on coronary plaque in adults with moderate hypertriglyceridemia using coronary computed tomography angiography (CCTA).
- At 12 months, olezarsen did not significantly change non-calcified plaque volume compared to placebo (placebo-adjusted difference 2.98%; p=0.36).
- No significant differences were observed in low-attenuation, calcified, or total plaque volumes after treatment.
- Olezarsen had a neutral effect on LDL cholesterol but reduced apolipoprotein B by ~16% over placebo at 6 months.